BCOR overexpression is a highly sensitive marker in round cell sarcomas with BCOR genetic abnormalities

Yu-Chien Kao, Yun Shao Sung, Lei Zhang, Achim A. Jungbluth, Shih Chiang Huang, Pedram Argani, Narasimhan P. Agaram, Angelica Zin, Rita Alaggio, Cristina R. Antonescu

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

With the advent of next-generation sequencing, an increasing number of novel gene fusions and other abnormalities have emerged recently in the spectrum of EWSR1-negative small blue round cell tumors (SBRCTs). In this regard, a subset of SBRCTs harboring either BCOR gene fusions (BCOR-CCNB3, BCOR-MAML3), BCOR internal tandem duplications (ITD), or YWHAE-NUTM2B share a transcriptional signature including high BCOR mRNA expression, as well as similar histologic features. Furthermore, other tumors such as clear cell sarcoma of kidney (CCSK) and primitive myxoid mesenchymal tumor of infancy also demonstrate BCOR ITDs and high BCOR gene expression. The molecular diagnosis of these various BCOR genetic alterations requires an elaborate methodology including custom BAC fluorescence in situ hybridization (FISH) probes and reverse transcription polymerase chain reaction assays. As these tumors show high level of BCOR overexpression regardless of the genetic mechanism involved, either conventional gene fusion or ITD, we sought to investigate the performance of an anti-BCOR monoclonal antibody clone C-10 (sc-514576) as an immunohistochemical marker for sarcomas with BCOR gene abnormalities. Thus we assessed the BCOR expression in a pathologically and genetically well-characterized cohort of 25 SBRCTs, spanning various BCOR-related fusions and ITDs and YWHAE-NUTM2B fusion. In addition, we included related pathologic entities such as 8 CCSKs and other sarcomas with BCOR gene fusions. As a control group we included 20 SBRCTs with various (non-BCOR) genetic abnormalities, 10 fusion-negative SBRCTs, 74 synovial sarcomas, 29 rhabdomyosarcomas, and other sarcoma types. In addition, we evaluated the same study group for SATB2 immunoreactivity, as these tumors also showed SATB2 mRNA upregulation. All SBRCTs with BCOR-MAML3 and BCOR-CCNB3 fusions, as well as most with BCOR ITD (93%), and all CCSKs showed strong and diffuse nuclear BCOR immunoreactivity. Furthermore, all SBRCTs with YWHAE-NUTM2B also were positive. SATB2 stain was also positive in tumors with YWHAE-NUTM2B, BCOR-MAML3, BCOR ITD (75%), BCOR-CCNB3 (71%), and a subset of CCSKs (33%). In conclusion, BCOR immunohistochemical stain is a highly sensitive marker for SBRCTs and CCSKs with BCOR abnormalities and YWHAE-rearrangements and can be used as a useful diagnostic marker in these various molecular subsets. SATB2 immunoreactivity is also present in the majority of this group of tumors.

Original languageEnglish
Pages (from-to)1670-1678
Number of pages9
JournalAmerican Journal of Surgical Pathology
Volume40
Issue number12
DOIs
Publication statusPublished - Nov 28 2016

Fingerprint

Sarcoma
Neoplasms
Gene Fusion
Coloring Agents
Clear Cell Sarcoma
Synovial Sarcoma
Messenger RNA
Rhabdomyosarcoma
Fluorescence In Situ Hybridization
Reverse Transcription
Up-Regulation
Clone Cells
Monoclonal Antibodies

Keywords

  • BCOR
  • Clear cell sarcoma kidney
  • Immunohistochemistry
  • SATB2
  • Small blue round cell tumor
  • Synovial sarcoma
  • YWHAE

ASJC Scopus subject areas

  • Anatomy
  • Surgery
  • Pathology and Forensic Medicine

Cite this

BCOR overexpression is a highly sensitive marker in round cell sarcomas with BCOR genetic abnormalities. / Kao, Yu-Chien; Sung, Yun Shao; Zhang, Lei; Jungbluth, Achim A.; Huang, Shih Chiang; Argani, Pedram; Agaram, Narasimhan P.; Zin, Angelica; Alaggio, Rita; Antonescu, Cristina R.

In: American Journal of Surgical Pathology, Vol. 40, No. 12, 28.11.2016, p. 1670-1678.

Research output: Contribution to journalArticle

Kao, Y-C, Sung, YS, Zhang, L, Jungbluth, AA, Huang, SC, Argani, P, Agaram, NP, Zin, A, Alaggio, R & Antonescu, CR 2016, 'BCOR overexpression is a highly sensitive marker in round cell sarcomas with BCOR genetic abnormalities', American Journal of Surgical Pathology, vol. 40, no. 12, pp. 1670-1678. https://doi.org/10.1097/PAS.0000000000000697
Kao, Yu-Chien ; Sung, Yun Shao ; Zhang, Lei ; Jungbluth, Achim A. ; Huang, Shih Chiang ; Argani, Pedram ; Agaram, Narasimhan P. ; Zin, Angelica ; Alaggio, Rita ; Antonescu, Cristina R. / BCOR overexpression is a highly sensitive marker in round cell sarcomas with BCOR genetic abnormalities. In: American Journal of Surgical Pathology. 2016 ; Vol. 40, No. 12. pp. 1670-1678.
@article{05701ff534db4e3b9e571f303017367a,
title = "BCOR overexpression is a highly sensitive marker in round cell sarcomas with BCOR genetic abnormalities",
abstract = "With the advent of next-generation sequencing, an increasing number of novel gene fusions and other abnormalities have emerged recently in the spectrum of EWSR1-negative small blue round cell tumors (SBRCTs). In this regard, a subset of SBRCTs harboring either BCOR gene fusions (BCOR-CCNB3, BCOR-MAML3), BCOR internal tandem duplications (ITD), or YWHAE-NUTM2B share a transcriptional signature including high BCOR mRNA expression, as well as similar histologic features. Furthermore, other tumors such as clear cell sarcoma of kidney (CCSK) and primitive myxoid mesenchymal tumor of infancy also demonstrate BCOR ITDs and high BCOR gene expression. The molecular diagnosis of these various BCOR genetic alterations requires an elaborate methodology including custom BAC fluorescence in situ hybridization (FISH) probes and reverse transcription polymerase chain reaction assays. As these tumors show high level of BCOR overexpression regardless of the genetic mechanism involved, either conventional gene fusion or ITD, we sought to investigate the performance of an anti-BCOR monoclonal antibody clone C-10 (sc-514576) as an immunohistochemical marker for sarcomas with BCOR gene abnormalities. Thus we assessed the BCOR expression in a pathologically and genetically well-characterized cohort of 25 SBRCTs, spanning various BCOR-related fusions and ITDs and YWHAE-NUTM2B fusion. In addition, we included related pathologic entities such as 8 CCSKs and other sarcomas with BCOR gene fusions. As a control group we included 20 SBRCTs with various (non-BCOR) genetic abnormalities, 10 fusion-negative SBRCTs, 74 synovial sarcomas, 29 rhabdomyosarcomas, and other sarcoma types. In addition, we evaluated the same study group for SATB2 immunoreactivity, as these tumors also showed SATB2 mRNA upregulation. All SBRCTs with BCOR-MAML3 and BCOR-CCNB3 fusions, as well as most with BCOR ITD (93{\%}), and all CCSKs showed strong and diffuse nuclear BCOR immunoreactivity. Furthermore, all SBRCTs with YWHAE-NUTM2B also were positive. SATB2 stain was also positive in tumors with YWHAE-NUTM2B, BCOR-MAML3, BCOR ITD (75{\%}), BCOR-CCNB3 (71{\%}), and a subset of CCSKs (33{\%}). In conclusion, BCOR immunohistochemical stain is a highly sensitive marker for SBRCTs and CCSKs with BCOR abnormalities and YWHAE-rearrangements and can be used as a useful diagnostic marker in these various molecular subsets. SATB2 immunoreactivity is also present in the majority of this group of tumors.",
keywords = "BCOR, Clear cell sarcoma kidney, Immunohistochemistry, SATB2, Small blue round cell tumor, Synovial sarcoma, YWHAE",
author = "Yu-Chien Kao and Sung, {Yun Shao} and Lei Zhang and Jungbluth, {Achim A.} and Huang, {Shih Chiang} and Pedram Argani and Agaram, {Narasimhan P.} and Angelica Zin and Rita Alaggio and Antonescu, {Cristina R.}",
year = "2016",
month = "11",
day = "28",
doi = "10.1097/PAS.0000000000000697",
language = "English",
volume = "40",
pages = "1670--1678",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - BCOR overexpression is a highly sensitive marker in round cell sarcomas with BCOR genetic abnormalities

AU - Kao, Yu-Chien

AU - Sung, Yun Shao

AU - Zhang, Lei

AU - Jungbluth, Achim A.

AU - Huang, Shih Chiang

AU - Argani, Pedram

AU - Agaram, Narasimhan P.

AU - Zin, Angelica

AU - Alaggio, Rita

AU - Antonescu, Cristina R.

PY - 2016/11/28

Y1 - 2016/11/28

N2 - With the advent of next-generation sequencing, an increasing number of novel gene fusions and other abnormalities have emerged recently in the spectrum of EWSR1-negative small blue round cell tumors (SBRCTs). In this regard, a subset of SBRCTs harboring either BCOR gene fusions (BCOR-CCNB3, BCOR-MAML3), BCOR internal tandem duplications (ITD), or YWHAE-NUTM2B share a transcriptional signature including high BCOR mRNA expression, as well as similar histologic features. Furthermore, other tumors such as clear cell sarcoma of kidney (CCSK) and primitive myxoid mesenchymal tumor of infancy also demonstrate BCOR ITDs and high BCOR gene expression. The molecular diagnosis of these various BCOR genetic alterations requires an elaborate methodology including custom BAC fluorescence in situ hybridization (FISH) probes and reverse transcription polymerase chain reaction assays. As these tumors show high level of BCOR overexpression regardless of the genetic mechanism involved, either conventional gene fusion or ITD, we sought to investigate the performance of an anti-BCOR monoclonal antibody clone C-10 (sc-514576) as an immunohistochemical marker for sarcomas with BCOR gene abnormalities. Thus we assessed the BCOR expression in a pathologically and genetically well-characterized cohort of 25 SBRCTs, spanning various BCOR-related fusions and ITDs and YWHAE-NUTM2B fusion. In addition, we included related pathologic entities such as 8 CCSKs and other sarcomas with BCOR gene fusions. As a control group we included 20 SBRCTs with various (non-BCOR) genetic abnormalities, 10 fusion-negative SBRCTs, 74 synovial sarcomas, 29 rhabdomyosarcomas, and other sarcoma types. In addition, we evaluated the same study group for SATB2 immunoreactivity, as these tumors also showed SATB2 mRNA upregulation. All SBRCTs with BCOR-MAML3 and BCOR-CCNB3 fusions, as well as most with BCOR ITD (93%), and all CCSKs showed strong and diffuse nuclear BCOR immunoreactivity. Furthermore, all SBRCTs with YWHAE-NUTM2B also were positive. SATB2 stain was also positive in tumors with YWHAE-NUTM2B, BCOR-MAML3, BCOR ITD (75%), BCOR-CCNB3 (71%), and a subset of CCSKs (33%). In conclusion, BCOR immunohistochemical stain is a highly sensitive marker for SBRCTs and CCSKs with BCOR abnormalities and YWHAE-rearrangements and can be used as a useful diagnostic marker in these various molecular subsets. SATB2 immunoreactivity is also present in the majority of this group of tumors.

AB - With the advent of next-generation sequencing, an increasing number of novel gene fusions and other abnormalities have emerged recently in the spectrum of EWSR1-negative small blue round cell tumors (SBRCTs). In this regard, a subset of SBRCTs harboring either BCOR gene fusions (BCOR-CCNB3, BCOR-MAML3), BCOR internal tandem duplications (ITD), or YWHAE-NUTM2B share a transcriptional signature including high BCOR mRNA expression, as well as similar histologic features. Furthermore, other tumors such as clear cell sarcoma of kidney (CCSK) and primitive myxoid mesenchymal tumor of infancy also demonstrate BCOR ITDs and high BCOR gene expression. The molecular diagnosis of these various BCOR genetic alterations requires an elaborate methodology including custom BAC fluorescence in situ hybridization (FISH) probes and reverse transcription polymerase chain reaction assays. As these tumors show high level of BCOR overexpression regardless of the genetic mechanism involved, either conventional gene fusion or ITD, we sought to investigate the performance of an anti-BCOR monoclonal antibody clone C-10 (sc-514576) as an immunohistochemical marker for sarcomas with BCOR gene abnormalities. Thus we assessed the BCOR expression in a pathologically and genetically well-characterized cohort of 25 SBRCTs, spanning various BCOR-related fusions and ITDs and YWHAE-NUTM2B fusion. In addition, we included related pathologic entities such as 8 CCSKs and other sarcomas with BCOR gene fusions. As a control group we included 20 SBRCTs with various (non-BCOR) genetic abnormalities, 10 fusion-negative SBRCTs, 74 synovial sarcomas, 29 rhabdomyosarcomas, and other sarcoma types. In addition, we evaluated the same study group for SATB2 immunoreactivity, as these tumors also showed SATB2 mRNA upregulation. All SBRCTs with BCOR-MAML3 and BCOR-CCNB3 fusions, as well as most with BCOR ITD (93%), and all CCSKs showed strong and diffuse nuclear BCOR immunoreactivity. Furthermore, all SBRCTs with YWHAE-NUTM2B also were positive. SATB2 stain was also positive in tumors with YWHAE-NUTM2B, BCOR-MAML3, BCOR ITD (75%), BCOR-CCNB3 (71%), and a subset of CCSKs (33%). In conclusion, BCOR immunohistochemical stain is a highly sensitive marker for SBRCTs and CCSKs with BCOR abnormalities and YWHAE-rearrangements and can be used as a useful diagnostic marker in these various molecular subsets. SATB2 immunoreactivity is also present in the majority of this group of tumors.

KW - BCOR

KW - Clear cell sarcoma kidney

KW - Immunohistochemistry

KW - SATB2

KW - Small blue round cell tumor

KW - Synovial sarcoma

KW - YWHAE

UR - http://www.scopus.com/inward/record.url?scp=84978741628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978741628&partnerID=8YFLogxK

U2 - 10.1097/PAS.0000000000000697

DO - 10.1097/PAS.0000000000000697

M3 - Article

C2 - 27428733

AN - SCOPUS:84978741628

VL - 40

SP - 1670

EP - 1678

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

IS - 12

ER -